CN102170876A - Physical endurance improving agent, anti-fatigue agent or fatigue recovering agent comprising amino acid composition as active ingredient - Google Patents

Physical endurance improving agent, anti-fatigue agent or fatigue recovering agent comprising amino acid composition as active ingredient Download PDF

Info

Publication number
CN102170876A
CN102170876A CN2009801394775A CN200980139477A CN102170876A CN 102170876 A CN102170876 A CN 102170876A CN 2009801394775 A CN2009801394775 A CN 2009801394775A CN 200980139477 A CN200980139477 A CN 200980139477A CN 102170876 A CN102170876 A CN 102170876A
Authority
CN
China
Prior art keywords
moles
mole
amino acid
agent
tyrosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2009801394775A
Other languages
Chinese (zh)
Other versions
CN102170876B (en
Inventor
有田宏行
常松雅子
越膳浩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Dairies Corp
Original Assignee
Meiji Dairies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Dairies Corp filed Critical Meiji Dairies Corp
Publication of CN102170876A publication Critical patent/CN102170876A/en
Application granted granted Critical
Publication of CN102170876B publication Critical patent/CN102170876B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The object aims to specify amino acid components or the concentrations of the amino acid components in an amino acid composition which are effective for the improvement in physical endurance, the prevention of fatigue or the recovery from fatigue, and also aims to reduce the amount of an amino acid component having poor solubility in an amino acid composition. Tyrosine is firstly identified as the amino acid that contributes to the improvement in physical endurance. The concentration of tyrosine (which has poor solubility in water) required for the improvement in physical endurance or the like is examined. As a result, an amino acid composition having high solubility, excellent physical endurance improving properties and the like can be discovered.

Description

Contain endurance improving agent, antifatigue or the fatigue recovery agent of amino acid composition as effective ingredient
Technical field
The present application belongs to the technical field of the compositions that is used to improve endurance, resisting fatigue or sets up.More specifically, the present application relates to and a kind ofly improves endurance, prevents fatigue or make the amino acid composition of fatigue recovery.
Background technology
Diseases due to habit disturbances such as diabetes can cause arteriosclerosis etc., are accompanied by aged tendency of population, the prevention of diseases due to habit disturbance and overcome and become great problem.For example it is said that the potential crowd of above-mentioned diseases due to habit disturbance only just has 2,000 ten thousand people in China.Therefore, as the countermeasure of diseases due to habit disturbance, carried out having used the health check-up health care guidance of metabolic syndrome notion.Motion is that effectively the raising of endurance is a big problem to the prevention of above-mentioned metabolic syndrome.
In addition, not only can be by training, can also or contain the medicine etc. of other effective ingredient by picked-up food, health product (supplement), attempt improving endurance.For example it is said that malic acid and citric acid have endurance reinforced effects (non-patent literature 1).And then, there is report to point out to exist in the protein of isolating specified molecular weight (57KDa) from Lac regis apis to improving cardio-pulmonary function and improving the composition (patent documentation 1) that endurance effectively promotes aerobatic exercise.
In addition, as the effective ingredient that improves endurance, known have cacao nib and/or its machining object (patent documentation 2), contain food compositions (patent documentation 3), the thioctic acid of coenzyme Q10 and (-)-hydroxycitric acid or contain thioctic acid and the compositions of creatine (patent documentation 4) etc.And, disclose the compositions that contains pantethin class and branched-chain amino acid and had the effect (patent documentation 5) that the endurance of preventing reduces.
On the other hand, the known amino acid compositions has multiple effect all the time.Amino acid composition from the class wasp can be used as the muscular strength retention agent, nourishes analeptic, infuses and use (patent documentation 6) with agent, supplementary, fatigue recovery agent or lactic acid generation regulator.And then, disclose with the fatigue recovery compositions of aspartic acid in WO2003-011056 number (patent documentation 7) as effective ingredient.In addition, disclose among the TOHKEMY 2008-105954 (patent documentation 8) with differentiation accelerator and the treatment for anemia agent of at least one in alanine, serine, glutamine, tyrosine, the agedoite as the bone marrow erythrocyte precursor of effective ingredient, and, disclose among the TOHKEMY 2008-081498 (patent documentation 9) with threonine and leucine and suppressed to use compositions as the lipopexia of effective ingredient.
Patent documentation 1: TOHKEMY 2001-172195 number
Patent documentation 2: TOHKEMY 2006-282576 number
Patent documentation 3: TOHKEMY 2004-81010 number
Patent documentation 4: TOHKEMY 2007-131609 number
Patent documentation 5: TOHKEMY 2006-16358 number
Patent documentation 6: No. the 2518692nd, Japan Patent
Patent documentation 7:WO2003-011056 number
Patent documentation 8: TOHKEMY 2008-105954 number
Patent documentation 9: TOHKEMY 2008-081498 number
Non-patent literature 1: Japanese hemorheology association will, the 6th volume, No. 2 (2003) 83-88 page or leaf
Summary of the invention
All the time, the known amino acid compositions has various active, but the composition that is suitable for improving endurance, resisting fatigue most or sets up still belongs to the unknown, and then, even for example for amino acid composition from the class wasp, do not have yet can specific amino acids compositions (mixture) in actually which kind of aminoacid to improve endurance etc. especially effectively, the amino acid concentration of which kind of degree is to improving endurance etc. effectively.
In addition, amino acid composition is for example mostly as liquid beverage or liquid preparation, but because the different solubility of every seed amino acid dissolves the composition that becomes problem so also exist in the amino acid composition.For example because tyrosine is low to the dissolubility of water, so expectation reduces its use amount as far as possible.
Therefore, the present application realizes following purpose: to improving endurance, resisting fatigue or set up effective aminoacid ingredient and concentration, reduce the low aminoacid ingredient of dissolubility simultaneously in the qualification amino acid composition.
All the time, the present application people etc. studies the various effects from the amino acid composition of class wasp.By the composition in the further investigation amino acid composition, identifying the aminoacid that helps improving endurance first is tyrosine, and then after the tyrosine that dissolubility is low at water improves the required concentration of endurance and inquire into, found a kind of dissolubility height and at the amino acid composition that improves excellence aspect the endurance.
This description comprises the content of putting down in writing as in Japanese patent application 2008-259678 number description of the application's basis for priority and/or the accompanying drawing.
The present application provides the aminoacid ingredient that improves endurance, resisting fatigue or set up first.
Description of drawings
Body weight change in [Fig. 1] expression experimentation (be worth is meansigma methods ± SE).Each is organized does not have significant difference between the body weight.
[Fig. 2] expression single is given with (value is meansigma methods ± SE) to the influence of swimming time.
[Fig. 3] expression is given repeatedly with (V-value is a meansigma methods ± SE) to the influence of swimming time.* p＜0.05, * *: p＜0.01 are with respect to contrast.
(value is the measured value of meansigma methods ± SE) to the glucose of [Fig. 4] expression in the blood.
(value is the measured value of meansigma methods ± SE) to the lactic acid of [Fig. 5] expression in the blood.*: p＜0.05 is with respect to contrast.
(value is the measured value of meansigma methods ± SE) to the free fatty of [Fig. 6] expression in the blood.* *: p＜0.005 is with respect to contrast.
(value is the measured value of meansigma methods ± SE) to [Fig. 7] expression hydroxybutyric acid.*: p＜0.05 is with respect to contrast.
(value is the measured value of meansigma methods ± SE) to [Fig. 8] expression creatine kinase.
(value is the measured value of meansigma methods ± SE) to the glycogen of [Fig. 9] expression liver and muscle (gastrocnemius).*: p＜0.05 is with respect to contrast.
(value is the measured value of meansigma methods ± SE) to the fatty tissue weight of [Figure 10] expression around the testis.*: P＜0.01 is with respect to contrast.
(value is the measured value of meansigma methods ± SE) to [Figure 11] expression gastrocnemius thigh quricipital muscle weight.*: p＜0.05 is with respect to contrast.
Whole publications, patent and the patent application of quoting in this description are directly introduced in this description as a reference.
The specific embodiment
1. improving the endurance resisting fatigue sets up
The present application comprises the amino acid composition that is used to improve endurance, and with the endurance improving agent of above-mentioned amino acid composition as effective ingredient.The amino acid composition that is used to improve endurance of the present application also can be made edible or medical or health food amino acid composition.The endurance improving agent of the present application is all effective to the raising of local endurance and general endurance.
In the mensuration of endurance, for example also can use the described method of following examples, measure, for example, in the mensuration of general endurance, also can measure by the expiration gas analysis of maximal oxygen intake (VO2max) by zoopery.Can be in the subject of motion, directly gather gas via gas mask and measure.
And then the present application also comprises following amino acid composition: when hope prevents fatigue by picked-up (give with) also can be as the amino acid composition of antifatigue in advance; And also can be when feeling fatigue as the amino acid composition of fatigue recovery agent by picked-up afterwards (give with).
2. endurance improving agent and have the amino acid composition of endurance raising effect
The present application comprises endurance improving agent, antifatigue, reaches the fatigue recovery agent, it is characterized in that, contains tyrosine at least as effective ingredient.More specifically, the present application comprises the endurance improving agent that only is made of tyrosine, antifatigue, and fatigue recovery agent, and also contains amino acid whose endurance improving agent except that tyrosine, antifatigue, and fatigue recovery agent.As the aminoacid except that tyrosine, for example can be branched-chain amino acid (BCAA) etc., particularly, can be for being selected from valine, leucine, isoleucine, arginine, glutamic acid, aspartic acid, alanine, proline, lysine, reaching any aminoacid more than a kind in the phenylalanine.
More specifically, can enumerate following endurance improving agent, antifatigue and/or fatigue recovery agent: (1) as amino acid composition, with endurance improving agent, antifatigue and/or the fatigue recovery agent as effective ingredient of the amino acid composition that only is made of tyrosine, valine, leucine, isoleucine, arginine, glutamic acid, aspartic acid, alanine, proline, lysine and phenylalanine; And (2) are with endurance improving agent, antifatigue and/or the fatigue recovery agent as effective ingredient of the amino acid composition that only is made of tyrosine, valine, leucine, isoleucine, arginine, glutamic acid, aspartic acid, alanine, proline, lysine, phenylalanine, threonine, glycine, serine, methionine, histidine and tryptophan.
In addition, the present application also comprises: (3) are with by endurance improving agent, antifatigue and/or the fatigue recovery agent as effective ingredient of the amino acid composition of following composition of proportions: 3～5 moles in tyrosine, 4～8 moles of valines, 2～12 moles of leucines, 3～9 moles of isoleucine, 0.1～5 mole of arginine, 0.1～4 mole in glutamic acid, 0.1～5 mole of aspartic acid, 0.1～12 mole of alanine, proline-4～30 mole, 5～11 moles of lysines, and 0.5～5 mole of phenylalanine; And (4) are with by the amino acid composition of the following composition of proportions endurance improving agent as effective ingredient, antifatigue, and/or fatigue recovery agent: 3～4 moles in tyrosine, 4～8 moles of valines, 2～12 moles of leucines, 3～9 moles of isoleucine, 0.1～5 mole of arginine, 0.1～4 mole in glutamic acid, 0.1～5 mole of aspartic acid, 0.1～12 mole of alanine, proline-4～30 mole, 5～11 moles of lysines, 0.5～5 mole of phenylalanine, 2～15 moles of threonine, 15～25 moles of glycine (or 20.5～25 moles), 0.1～5 mole of serine, 0.1～5 mole of methionine, 0.1～5 mole of histidine, reach 0.1～5 mole of tryptophan.
Also comprise in the present application: (5) are with by endurance improving agent, antifatigue and/or the fatigue recovery agent as effective ingredient of the amino acid composition of following composition of proportions: 3.5～4 moles in tyrosine, 5～7 moles of valines, 6～8 moles of leucines, 4～6 moles of isoleucine, 3～5 moles of arginine, 3～5 moles in glutamic acid, 0.1～1 mole of aspartic acid, 6～8 moles of alanine, 15～20 moles of proline, 8～10 moles of lysines, and phenylalanine-3,4-quinone～5 mole; And (6) are with by the amino acid composition of the following composition of proportions endurance improving agent as effective ingredient, antifatigue, and/or fatigue recovery agent: 3.8～4 moles in tyrosine, 5.8～6 moles of valines, 6.2～6.4 moles of leucines, 4.5～4.7 moles of isoleucine, 3.5～3.7 moles of arginine, 3.2～3.4 moles in glutamic acid, 0.15～0.17 mole of aspartic acid, 6.1～6.3 moles of alanine, 18～19 moles of proline, 8.7～8.9 moles of lysines, phenylalanine-3,4-quinone .8～4 mole, 7.2～7.4 moles of threonine, 19～21 moles of glycine (or 20.5～21 moles), 2.5～2.7 moles of serines, 0.53～0.55 mole of methionine, 2.6～2.8 moles of histidine, reach 2.2～2.4 moles of tryptophans.
At this moment, more specifically, compare from the amino acid composition (V.A.A.M.) of class wasp with existing, the concentration of tyrosine is preferably 50～90%, more preferably be 70～90%, more preferably 75～85%, be preferably about 80% especially, can enumerate following aqueous solution: preferably the concentration of tyrosine is set at 2.4～4.3 moles of % (3.5～6.3 weight %), more preferably 3.3～4.3 moles of % (4.8～6.3 weight %), more preferably 3.6～4.1 moles of % (5.2～5.9 weight %), and tyrosine is contained in the aqueous solution with 0.05～0.065 mole of %.
As preferred amino acid composition, can enumerate the amino acid composition that constitutes by following aminoacid, that is the tyrosine of, about 3.9 moles (about 5.5 weight portions), the valine of about 6.0 moles (about 5.6 weight portions), the leucine of about 6.3 moles (about 6.5 weight portions), the isoleucine of about 4.6 moles (about 4.8 weight portions), the arginine of about 3.6 moles (about 5.0 weight portions), the glutamic acid of about 3.3 moles (about 3.8 weight portions), the aspartic acid of about 0.16 mole (about 0.22 weight portion), the alanine of about 6.3 moles (about 4.4 weight portions), the proline of about 18.4 moles (about 16.8 weight portions), the lysine of about 8.8 moles (about 12.8 weight portions), the phenylalanine of about 3.9 moles (about 5.1 weight portions), the threonine of about 7.3 moles (about 6.9 weight portions), the glycine of about 19.5 moles (about 11.6 weight portions), the serine of about 2.5 moles (about 2.1 weight portions), the methionine of about 0.54 mole (about 0.64 weight portion), the histidine of about 2.6 moles (about 3.2 weight portions), and the tryptophan of about 2.2 moles (about 3.6 weight portions).
3. the use form of the endurance improving agent of the present application, antifatigue and/or fatigue recovery agent
The use form of the endurance improving agent of the present application, antifatigue or fatigue recovery agent is not particularly limited, and can be used for medical treatment, also can be used for diet, the auxiliary diet of nutrition.
Be used under the situation of medical treatment, can by oral give with, rectum is given with, injection or transfusion give with etc. common being used with approach.Oral give with situation under, mixing in the lump such as above-mentioned composition itself or the carrier that pharmaceutically allows, excipient, diluent can be made powder, granule, tablet, capsule, lozenge, syrup etc.In addition,, for example can add suitable reducing, isotonic agent etc., be dissolved in sterile purified water and use and get final product as injection.
The endurance improving agent of the present application, antifatigue or fatigue recovery agent can be adopted suitable dosage forms such as powder, granule, tablet, capsule, liquid preparation.When preparation, can add auxiliary agent commonly used in the preparationizations such as excipient, binding agent, disintegrating agent, lubricant.As excipient, comprise starch, lactose, white sugar, methylcellulose, carboxymethyl cellulose, sodium alginate, calcium hydrogen phosphate, synthetic aluminium silicate, microcrystalline Cellulose, polyvinylpyrrolidone (PVP), hydroxypropyl starch (HPS) etc.In addition, as binding agent, comprise the aqueous solution of starch, microcrystalline Cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone (PVP), arabic gum powder, gelatin, glucose, white sugar etc. or their hydrous ethanol solution etc.As disintegrating agent, comprise starch, carboxymethyl cellulose, carboxymethylcellulose calcium, microcrystalline Cellulose, hydroxypropyl starch, calcium phosphate etc.As lubricant, comprise Brazil wax, light anhydrous silicic acid, synthetic aluminium silicate, natural aluminium silicate, synthetic magnesium silicate, hydrogenated oil and fat, hydrogenated vegetable oil derivant (Sterotex HM), Oleum sesami, white beeswax, titanium oxide, Aluminium Hydroxide gel stearic acid, calcium stearate, magnesium stearate, Talcum, calcium hydrogen phosphate, sodium lauryl sulphate etc.
The endurance improving agent that contains amino acid composition, antifatigue or the fatigue recovery agent of the present application are very safe, give and amount so can set it in scope very widely.Generally, can consider to approach, comprise giving and various factorss such as age of object animal, body weight, symptom of people, suitably set.The present application is not limited to this, as suitable effective ingredient, and preferred 0.3g～8g/kg/ days, more preferably 0.4g～5g/kg/ days, more preferably 0.5g～3g/kg/ days.
The endurance improving agent of the present application, antifatigue or fatigue recovery agent can be given and 100～500ml, 1～3 time with the form of 0.3～60 weight % solution, preferred 1.0～2.0 weight % solution in per 1 day.During for injection, give and 100～400ml, preferred 150～300ml for per 1 time with the form of 0.3～6.0 weight % solution.In addition, the endurance improving agent of the present application, antifatigue or fatigue recovery agent, can adopt oral give AOI oral give with (intramuscular, subcutaneous, intravenous, suppository, percutaneous etc.) in any mode.
Under edible situation, the endurance improving agent of the present application, antifatigue or fatigue recovery agent can directly eat, and also can make the additive that adds in the various food.In addition, also the amino acid composition of the present application can be dissolved in water and make beverage, in these cases, can also further add other nutritional labelings, for example water-soluble vitamins, taurine etc.In order to improve hobby, can add acids (acid flavoring) such as salt, citric acids such as sodium chloride and/or other proper flavor and make beverage.At this moment, in order to improve stability, also can further add pH regulator agent, chelating agen.
The endurance improving agent of the present application, antifatigue or fatigue recovery agent are given continuously with comparatively desirable, preferably give with more than 1 week.
Embodiment
In following examples, use following experimental sample.
(A) experimental sample: be suspended in distilled water, as described below preparation.
(1) DW (distilled water)=contrast (control)
(2) from the aqueous solution (aqueous solution of V.A.A.M.) of the amino acid composition of class wasp: 500mg/kg.Need to prove, shown in it is composed as follows.
The tyrosine of about 4.8 moles (about 6.9 weight portions), the valine of about 6.0 moles (about 5.6 weight portions), the leucine of about 6.3 moles (about 6.5 weight portions), the isoleucine of about 4.6 moles (about 4.8 weight portions), the arginine of about 3.6 moles (about 5.0 weight portions), the glutamic acid of about 3.3 moles (about 3.8 weight portions), the aspartic acid of about 0.16 mole (about 0.22 weight portion), the alanine of about 6.3 moles (about 4.4 weight portions), the proline of about 18.4 moles (about 16.8 weight portions), the lysine of about 8.8 moles (about 12.8 weight portions), the phenylalanine of about 3.9 moles (about 5.1 weight portions), the threonine of about 7.3 moles (about 6.9 weight portions), the glycine of about 19.5 moles (about 11.6 weight portions), the serine of about 2.5 moles (about 2.1 weight portions), the methionine of about 0.54 mole (about 0.64 weight portion), the histidine of about 2.6 moles (about 3.2 weight portions), and the tryptophan of about 2.2 moles (about 3.6 weight portions).
(3) only tyrosine is reduced to 80% aqueous solution: 500mg/kg from the amino acid composition of class wasp.Need to prove, in following content and accompanying drawing, be denoted by Tyr 80% sometimes.
(4) only tyrosine is reduced to 20% aqueous solution: 500mg/kg from the amino acid composition of class wasp.Need to prove, in following content and accompanying drawing, be denoted by Tyr 20% sometimes.
(B) breakdown test is according to Jpn.J.Phys.Fitness Sports Med.1995, and the method for putting down in writing among the 44:225-238 is carried out.Generally, at room temperature make mice (respectively organizing 10) fasting after 16 hours, amino acid composition made the aqueous solution of 1.8 weight %, with 37.5 μ l/g body weight carry out oral give with, then, at room temperature allow it have a rest 30 minutes.Mice is put into the flowing water pond, and (the cylinder type tank at diameter 32cm, dark 30cm adds entry, remain on 35 ℃, utilize the circulating device manufacturing speed to be 8m/ minute current) in and the plummet (weight) of following provisions is contained on the mousetail, make its swimming, measure critical swimming time.
(C) experimental technique: implement according to following order.
(1), as index, is divided into 4 groups of (groupings, 1 group: n=10) with the evaluation of endurance with the ddY male mice domestication in 4 ages in week after 12 days.Need to prove, set this time point and be-1week (1 week).Body weight change in whole experimental session is shown in Fig. 1.Each organizes body weight does not have significant difference.
In the endurance of following (2)～(4) was estimated, the plummet that will be equivalent to body weight 5% was contained on the mousetail, measures critical swimming time.
(2) certainly after 1 week of swimming grouping beginning, begin oral giving and above-mentioned experimental sample, begin to after the 1st day, measure swimming time (single is given and tested).Need to prove, set this time point and be 0week (0 week=0 day).At this moment, to each group oral give promptly contrasted with above-mentioned experimental sample, from the aqueous solution (V.A.A.M. aqueous solution) of the amino acid composition of class wasp, only tyrosine is reduced to 80% from the aqueous solution (Tyr 80%) of the amino acid composition of class wasp or only tyrosine is reduced to 20% aqueous solution (Tyr 20%) from the amino acid composition of class wasp.
The above results is shown in Fig. 2.As shown in Figure 2, single give and the time, do not confirm swimming time and prolong.
(3) afterwards, oral the giving and, every day 1 time, totally 7 weeks of proceeding experimental sample.In this period, solid food (the Labo MR Stock: Japanese agricultural production industry) that the fundamental freedom picked-up is common.But, in the mensuration of swimming time, blood sampling, dissection, begin its fasting from last evening (22 o'clock).
(4) per 1 week is carried out the mensuration of swimming time, up to 5week (the 5th week).In the mensuration day of swimming time, before swimming begins 30 minutes, oral giving and experimental sample.
It the results are shown in Fig. 3.100% group in tyrosine (Tyr) is compared with matched group with 80% group, from giving and the 1st week of beginning, confirms swimming time and prolongs significantly.Organize and do not confirm between 80% group difference at Tyr100%.The Tyr20% group is compared with matched group, even giving and the prolongation that does not also confirm swimming time the 5th week that begins.
(5) beginning oral give with experimental sample after 6week (the 6th week), the plummet that will be equivalent to body weight 5% is contained on the mousetail, make its swimming 15 minutes, afterwards, take a blood sample, measure the fatty acid (NEFA, Non-esterified fatty acid) that dissociates in lactic acid value, the blood in blood glucose value, the blood) value.Need to prove, give with preceding, give with 30 minutes after (before being about to motion) also take a blood sample, similarly measure with above-mentioned.Use Glucose CII-Test Wako (with the pure medicine of light Co., Ltd. system) when measuring blood glucose value, use Detamina-LA (consonance Medex Co., Ltd. system) when measuring the lactic acid value, use NEFA C-Test Wako (with the pure medicine of light Co., Ltd. system) when measuring the free-fat acid number.
The measurement result of blood glucose value is shown in Fig. 4.Dextrose equivalent in the blood of each group does not confirm significant difference.
The measurement result of lactic acid value is shown in Fig. 5 in the blood.Give with preceding, give with 30 minutes after (before being about to motion), do not confirm significant difference in the lactic acid value in each blood of organizing.80% group of 100% group of Tyr and Tyr compare with matched group, after motion just, confirm the lactic acid value and reduce significantly, and the lactic acid that suppresses associated movement raises.
The measurement result of free fatty acid (NEFA) value is shown in Fig. 6 in the blood.20% group of 80% group of 100% group of Tyr, Tyr, Tyr compare with matched group, all confirm in just motion back free fatty (NEFA) value to raise significantly.
(6) similarly at 7week (the 7th week), similarly take a blood sample, measure ketone (3-hydroxybutyric acid, 3-Hydroxybutylic acid) value, creatine kinase (CK, Creatine kinase) value.Use Ketolex " three He " (Sanwa Chemical Co., Ltd's system) during the mensuration of ketone, use CPKII-Test Wako (with the pure medicine of light Co., Ltd. system) during the mensuration of creatine kinase.
The measurement result of ketone is shown in Fig. 7.Along with motion, hydroxybutyric acid (ketone) value all raises, and 80% group of 100% group of Tyr and Tyr compare with matched group, can confirm to raise significantly at just motion back ketone.
The measurement result of creatine kinase is shown in Fig. 8.Along with motion, creatine kinase (CK) value all raises, but does not confirm significant difference between the creatine kinase value of each group.
(7) begin to 8week (the 8th week), each component is become non-exercise group and exercise group (swimming).
Similarly, dissect mice, measure organ weights (fatty gastrocnemius thigh musculus quadriceps around the liver kidney spleen epididymis) in the 8th week.In liver and the gastrocnemius, also measure the amount of glycogen.Use Glucose CII-Test Wako (with the pure medicine of light Co., Ltd. system) when measuring glycogen.
The plummet that will be equivalent to body weight 5% is contained on the tail of half mice, makes its swimming dissect (exercise group=have motion) to it immediately after 15 minutes.For the mice that remains half, do not swim and directly dissect (non-exercise group=not motion).
The measurement result of glycogen amount is shown in Fig. 9.In non-exercise group (not having motion), the liver of each group and the glycogen amount of muscle do not confirm difference.On the other hand, in exercise group (motion is arranged), 100% group of Tyr compares with matched group with 80% group, and the glycogen amount that confirms liver and muscle raises significantly.
In addition, the measurement result of organ weights is shown in Figure 10 and Figure 11.100% group of Tyr compares with matched group, confirms fatty tissue weight and reduce significantly around testis.In addition, 100% group of Tyr compares with matched group, confirms gastrocnemius weight and thigh musculus quadriceps weight increases significantly.Do not confirm the difference of other internal organs (liver kidney spleen).
Utilizability on the industry
The present application can be as being conducive to the raising endurance such as sports and competitions person, physical labourer and domestic animal, the medicine that recovers fatigue, antifatigue etc., health care healthy food, beverage or feed.

Claims (10)

1. endurance improving agent, antifatigue or fatigue recovery agent, with tyrosine as effective ingredient.
2. endurance improving agent, antifatigue or fatigue recovery agent, with the amino acid composition that contains tyrosine as effective ingredient.
3. endurance improving agent as claimed in claim 2, antifatigue or fatigue recovery agent, wherein, the amino acid composition that contains tyrosine only is made of tyrosine, valine, leucine, isoleucine, arginine, glutamic acid, aspartic acid, alanine, proline, lysine and phenylalanine.
4. endurance improving agent as claimed in claim 2, antifatigue or fatigue recovery agent, wherein, the amino acid composition that contains tyrosine only is made of tyrosine, valine, leucine, isoleucine, arginine, glutamic acid, aspartic acid, alanine, proline, lysine, phenylalanine, threonine, glycine, serine, methionine, histidine and tryptophan.
5. endurance improving agent as claimed in claim 3, antifatigue or fatigue recovery agent, wherein, the amino acid composition that contains tyrosine is made of the aminoacid of following ratio: 0.5～5 mole of 3～5 moles in tyrosine, 4～8 moles of valines, 2～12 moles of leucines, 3～9 moles of isoleucine, 0.1～5 mole of arginine, 0.1～4 mole in glutamic acid, 0.1～5 mole of aspartic acid, 0.1～12 mole of alanine, proline-4～30 mole, 5～11 moles of lysines and phenylalanine.
6. endurance improving agent as claimed in claim 4, antifatigue, or fatigue recovery agent, wherein, the amino acid composition that contains tyrosine is made of the aminoacid of following ratio: 3～4 moles in tyrosine, 4～8 moles of valines, 2～12 moles of leucines, 3～9 moles of isoleucine, 0.1～5 mole of arginine, 0.1～4 mole in glutamic acid, 0.1～5 mole of aspartic acid, 0.1～12 mole of alanine, proline-4～30 mole, 5～11 moles of lysines, 0.5～5 mole of phenylalanine, 2～15 moles of threonine, 15～25 moles of glycine, 0.1～5 mole of serine, 0.1～5 mole of methionine, 0.1～5 mole of 0.1～5 mole of histidine and tryptophan.
7. endurance improving agent as claimed in claim 4, antifatigue, or fatigue recovery agent, wherein, the amino acid composition that contains tyrosine is made of the aminoacid of following ratio: 3.5～4 moles in tyrosine, 5～7 moles of valines, 6～8 moles of leucines, 4～6 moles of isoleucine, 3～5 moles of arginine, 3～5 moles in glutamic acid, 0.1～1 mole of aspartic acid, 6～8 moles of alanine, 15～20 moles of proline, 8～10 moles of lysines, phenylalanine-3,4-quinone～5 mole, 7～9 moles of threonine, 15～25 moles of glycine, 2～4 moles of serines, 0.5～1.5 mole of methionine, 2～4 moles of 2～4 moles of histidine and tryptophans.
8. endurance improving agent as claimed in claim 4, antifatigue, or fatigue recovery agent, wherein, the amino acid composition that contains tyrosine is made of the aminoacid of following ratio: 3.8～4 moles in tyrosine, 5.8～6 moles of valines, 6.2～6.4 moles of leucines, 4.5～4.7 moles of isoleucine, 3.5～3.7 moles of arginine, 3.2～3.4 moles in glutamic acid, 0.15～0.17 mole of aspartic acid, 6.1～6.3 moles of alanine, 18～19 moles of proline, 8.7～8.9 moles of lysines, phenylalanine-3,4-quinone .8～4 mole, 7.2～7.4 moles of threonine, 19～21 moles of glycine, 2.5～2.7 moles of serines, 0.53～0.55 mole of methionine, 2.2～2.4 moles of 2.6～2.8 moles of histidine and tryptophans.
9. as each described endurance improving agent, antifatigue or fatigue recovery agent in the claim 1～8, it is characterized in that tyrosine is contained in the aqueous solution with 0.05～0.065 mole of %.
10. diet product or nutrition are auxiliary with the diet product, contain each described endurance improving agent, antifatigue or fatigue recovery agent in the aforesaid right requirement 1～9.
CN2009801394775A 2008-10-06 2009-10-06 Physical endurance improving agent, anti-fatigue agent or fatigue recovering agent comprising amino acid composition as active ingredient Active CN102170876B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008-259678 2008-10-06
JP2008259678 2008-10-06
PCT/JP2009/067387 WO2010041647A1 (en) 2008-10-06 2009-10-06 Physical endurance improving agent, anti-fatigue agent or fatigue recovering agent comprising amino acid composition as active ingredient

Publications (2)

Publication Number Publication Date
CN102170876A true CN102170876A (en) 2011-08-31
CN102170876B CN102170876B (en) 2013-12-04

Family

ID=42100597

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801394775A Active CN102170876B (en) 2008-10-06 2009-10-06 Physical endurance improving agent, anti-fatigue agent or fatigue recovering agent comprising amino acid composition as active ingredient

Country Status (4)

Country Link
JP (1) JPWO2010041647A1 (en)
CN (1) CN102170876B (en)
HK (1) HK1159507A1 (en)
WO (1) WO2010041647A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105192810A (en) * 2015-10-29 2015-12-30 常州亚当生物技术有限公司 Compound amino acid beverage as well as preparation method and application thereof
CN105311061A (en) * 2014-05-31 2016-02-10 陈光健 Pharmaceutical composition having wound surface healing effect, preparation method and applications thereof
CN105640995A (en) * 2016-03-01 2016-06-08 四川好医生攀西药业有限责任公司 Pharmaceutical composition and applications thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6496599B2 (en) * 2014-06-13 2019-04-03 花王株式会社 Muscle protein synthesis signal activator
JP2017088616A (en) * 2017-02-09 2017-05-25 株式会社東洋新薬 Kaempferia parviflora-containing compositions
US10413563B2 (en) * 2017-05-10 2019-09-17 Emerald Neuro-Recover, LLC Neurochemical wellness program
JP7275499B2 (en) * 2018-08-27 2023-05-18 味の素株式会社 Composition for improving brain function
JP7264169B2 (en) * 2018-08-31 2023-04-25 味の素株式会社 Intermittent endurance improver or blood pH raiser
KR20230047371A (en) * 2020-07-02 2023-04-07 유니버시티 오브 플로리다 리서치 파운데이션, 인크. Formulations to promote hydration and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03128318A (en) * 1989-06-14 1991-05-31 Rikagaku Kenkyusho Amino acid composition acting on muscle and nervous system
WO2003011056A1 (en) * 2001-07-31 2003-02-13 Ajinomoto Co., Inc. Ergogenic food compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2873497B2 (en) * 1990-09-03 1999-03-24 理化学研究所 Lipid metabolism regulator
JP3128318B2 (en) * 1992-03-18 2001-01-29 株式会社クラレ Method for producing cationic dye dyeable polyester microfiber
JP4528925B2 (en) * 2003-05-30 2010-08-25 独立行政法人理化学研究所 Amino acid composition and fluid replacement
JP5604673B2 (en) * 2005-01-31 2014-10-15 隆宣 山本 Composition for recovery or prevention of fatigue of central nervous system
WO2007142231A1 (en) * 2006-06-08 2007-12-13 Meiji Dairies Corporation Agent for improvement in blood fluidity
CN101454000A (en) * 2006-06-13 2009-06-10 明治乳业株式会社 Anti-fatigue agent containing amino acid composition
AU2008220128B2 (en) * 2007-02-28 2013-07-11 Meiji Co., Ltd. Amino acid composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03128318A (en) * 1989-06-14 1991-05-31 Rikagaku Kenkyusho Amino acid composition acting on muscle and nervous system
WO2003011056A1 (en) * 2001-07-31 2003-02-13 Ajinomoto Co., Inc. Ergogenic food compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AVRAHAM, Y. ET AL: "Tyrosine improves appetites,cognition, and exercise tolerance in activity anorexia", 《MEDICINE AND SCIENCE IN SPORTS AND EXERCISE》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105311061A (en) * 2014-05-31 2016-02-10 陈光健 Pharmaceutical composition having wound surface healing effect, preparation method and applications thereof
CN105192810A (en) * 2015-10-29 2015-12-30 常州亚当生物技术有限公司 Compound amino acid beverage as well as preparation method and application thereof
CN105640995A (en) * 2016-03-01 2016-06-08 四川好医生攀西药业有限责任公司 Pharmaceutical composition and applications thereof

Also Published As

Publication number Publication date
HK1159507A1 (en) 2012-08-03
JPWO2010041647A1 (en) 2012-03-08
CN102170876B (en) 2013-12-04
WO2010041647A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
CN102170876B (en) Physical endurance improving agent, anti-fatigue agent or fatigue recovering agent comprising amino acid composition as active ingredient
Trommelen et al. Resistance exercise augments postprandial overnight muscle protein synthesis rates
Zabala et al. Bicarbonate ingestion has no ergogenic effect on consecutive all out sprint tests in BMX elite cyclists
Robergs et al. Biochemistry of exercise-induced metabolic acidosis
Hazell et al. Two minutes of sprint-interval exercise elicits 24-hr oxygen consumption similar to that of 30 min of continuous endurance exercise
US20070286909A1 (en) Amino acid compositions
Burke et al. Effect of intake of different dietary protein sources on plasma amino acid profiles at rest and after exercise
AU2016262125B2 (en) Amino acid supplementation
CN105451578A (en) Chromatographic separation of sugars using blend of cation exchange resins
ES2393786T3 (en) Method to improve ventilatory efficiency
Ortiz de Zevallos et al. Sex differences in the effects of inorganic nitrate supplementation on exercise economy and endurance capacity in healthy young adults
Eshbo’riyev et al. Effectiveness of probiotics in preventing disorders of calcium-phosphorus metabolism in rabbits
US11331318B2 (en) Arterial oxygen saturation degree improver
US20070021506A1 (en) Stress relieving composition
Trujillo et al. Nutritional assessment in the critically ill
JP6677775B2 (en) Muscle builders
Gardner et al. Ligation of the left aorta in alligators affects acid–base balance: a role for the R→ L shunt
CN109223766A (en) Improve the composition and preparation process that microcirculation in human body improves the immunity of the human body
Rogers The Acute Effects of Citrulline Malate and Bonded Arginine Silicate Supplementation on Vasodilation of Young Adults
Komorowski et al. Inositol-Stabilized Arginine Silicate: A Novel Nitric Oxide-Boosting Ingredient for Sports Nutrition and Improved Cognition
Tinnion Sodium citrate: refining ingestion protocols to better understand its ergogenic potential
CN112075635A (en) Use of coconut oil for the preparation of a product for increasing energy metabolism and helping to maintain body temperature in cold environments
Nose Impact of 5-aminolevulinic acid with iron supplementation on exercise 2 efficiency and home-based walking training achievement in older 3 women 4
Yasuda et al. Association of Protein Intake at Three Meals With Muscle Mass in Healthy Young Subjects: 2023 Board# 179 May 30 2: 00 PM-3: 30 PM
Pinto Effects of different doses of B-alanine supplementation in the performance and body composition of elite rowers

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Tokyo, Japan, Japan

Applicant after: Meiji Co., Ltd.

Address before: Tokyo, Japan, Japan

Applicant before: Meiji Dairies Corporation

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: MEIJI DAIRIES CORPORATION TO: MEIJI KK

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1159507

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1159507

Country of ref document: HK